703 related articles for article (PubMed ID: 30197476)
21. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
22. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
23. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
24. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.
Gui Y; Khan MGM; Bobbala D; Dubois C; Ramanathan S; Saucier C; Ilangumaran S
World J Gastroenterol; 2017 Sep; 23(36):6639-6649. PubMed ID: 29085209
[TBL] [Abstract][Full Text] [Related]
25. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.
Ozen E; Gozukizil A; Erdal E; Uren A; Bottaro DP; Atabey N
PLoS One; 2012; 7(8):e42717. PubMed ID: 22912725
[TBL] [Abstract][Full Text] [Related]
26. Met as a therapeutic target in HCC: facts and hopes.
Giordano S; Columbano A
J Hepatol; 2014 Feb; 60(2):442-52. PubMed ID: 24045150
[TBL] [Abstract][Full Text] [Related]
27. Diospyros kaki leaves inhibit HGF/Met signaling-mediated EMT and stemness features in hepatocellular carcinoma.
Ko H; Huh G; Jung SH; Kwon H; Jeon Y; Park YN; Kim YJ
Food Chem Toxicol; 2020 Aug; 142():111475. PubMed ID: 32522589
[TBL] [Abstract][Full Text] [Related]
28. Targeting hepatocyte growth factor/c-mesenchymal-epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies.
Yu J; Chen GG; Lai PBS
Med Res Rev; 2021 Jan; 41(1):507-524. PubMed ID: 33026703
[TBL] [Abstract][Full Text] [Related]
29. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
30. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.
Korhan P; Erdal E; Atabey N
Biochem Biophys Res Commun; 2014 Aug; 450(4):1304-12. PubMed ID: 25058462
[TBL] [Abstract][Full Text] [Related]
31. Association between the HGF/c‑MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (Review).
Meng W; Chen T
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34278495
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
[TBL] [Abstract][Full Text] [Related]
33. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
[No Abstract] [Full Text] [Related]
34. Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53.
Liu WT; Jing YY; Yu GF; Chen H; Han ZP; Yu DD; Fan QM; Ye F; Li R; Gao L; Zhao QD; Wu MC; Wei LX
Cell Cycle; 2016; 15(7):886-94. PubMed ID: 27077227
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.
Ogunwobi OO; Puszyk W; Dong HJ; Liu C
PLoS One; 2013; 8(5):e63765. PubMed ID: 23723997
[TBL] [Abstract][Full Text] [Related]
36. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma.
Korhan P; Erdal E; Kandemiş E; Cokaklı M; Nart D; Yılmaz F; Can A; Atabey N
PLoS One; 2014; 9(8):e105278. PubMed ID: 25148256
[TBL] [Abstract][Full Text] [Related]
37. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.
Zhang R; Gao X; Zuo J; Hu B; Yang J; Zhao J; Chen J
Cancer Sci; 2020 Feb; 111(2):406-417. PubMed ID: 31785057
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
39. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
40. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]